Skip to content
OpenCapital
Get started
Income StatementBalance SheetCash FlowSegments
Neurocrine Biosciences logo

Neurocrine Biosciences Income Statement

Revenue, expenses, and profitability over time

Neurocrine Biosciences generated $3.1B in trailing twelve-month revenue, up 0.3% year-over-year. Net income was $668.6M with a 21.55% net margin. Gross margin stands at 98.17% and operating margin at 25.43%. Diluted EPS is $6.49, which grew 1.2% year-over-year. Based on the Q1 2026 filing.

Total Revenue (TTM)$3.1BGross Profit (TTM)$3.0BOperating Income (TTM)$788.9MNet Income (TTM)$668.6MEps Diluted (TTM)$6.49
Latest FilingQ1 2026
Report Date2026-05-05
Market Cap$16.4B
P/E Ratio24.47
ROE22.5%

Earnings Per Share

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Basic earnings per share$1.03$0.08$1.09$2.11$1.54$1.97
Diluted earnings per share$1.00$0.08$1.06$2.04$1.48$1.91
Weighted-average shares, basic100.4M99.7M99M99.4M99.5M100.5M
Weighted-average shares, diluted103.7M102.5M101M102.5M102.5M103.4M

Other Income & Expense

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Gain (loss) on disposal of assets—$0———$28.6M
Gain on retained interest in Sandisk-$1.9M-$30.6M-$6.7M$30.6M—$25.3M
Investment income and other, net$22.5M$21.7M$20.6M$22.2M$25.8M$28.1M
Other income (expense), net—-$8.9M$13.9M$52.8M$28.5M$53.4M

Operating Income

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Gross profit$618.4M$563.4M$676.2M$780.9M$787.9M$800.7M
Operating income$142M$23.6M$145.6M$239M$210.9M$193.4M

Income Before Tax

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Income before income taxes$162.6M$14.7M$159.5M$291.8M$239.4M$246.8M

Tax

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Income tax expense$59.5M$6.8M$52M$82.3M$85.7M$48.9M

Net Income

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Net income$103.1M$7.9M$107.5M$209.5M$153.7M$197.9M

Other

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Comprehensive Income (Loss), Net of Tax, Attributable to Parent$94.4M$11.1M$111M$210.2M$153.6M$185.2M
Depreciation$6.2M$6.6M$6.3M$6.7M$6.4M$7.2M
Gain on sale of business and assets—$0———$28.6M
Income taxes paid$73M$600K$71.9M$1.1M$7.8M$300K
Accounts payable and other current liabilities$77.3M-$3M$30.9M$55.8M$76.5M-$14.3M
Increase (Decrease) in Accounts Receivable$0$36.9M$79.7M$132.3M—$81.4M
Increase (Decrease) in Inventories$11.6M$1.7M-$2.1M$12.3M$3.4M-$4.3M
Unrealized gains (losses) on available-for-sale securities-$5.1M$1.7M$2.7M-$900K$0-$12.7M
Payments to Acquire Property, Plant, and Equipment$7.3M$10.7M$12.5M$13.2M$0$9.1M
Proceeds from Issuance of Common Stock$10M$32.1M$14.4M$45.6M$37.3M$23.6M
Acquired in-process research and development expenses$3M$100K$0$300K$17M$21.2M
Research and development expense$185.6M$263.2M$244.3M$250M$258.2M$296.2M
Revenue From Contract With Customer Excluding Assessed Tax$627.7M$572.6M$687.5M$794.9M$805.5M$814.5M
Stock-based compensation$66.4M$52.8M$52.8M$53.7M$58.6M$57.2M

Operating Expenses

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Research and development$185.6M$263.2M$244.3M$250M$258.2M$296.2M
Selling, general and administrative$287.8M$276.5M$286.3M$291.6M$301.8M$318.5M
Total operating expenses$485.7M$549M$541.9M$555.9M$594.6M$621.1M

Cost of Revenue

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Total cost of revenue$9.3M$9.2M$11.3M$14M$17.6M$13.8M

Revenue

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Total revenue$627.7M$572.6M$687.5M$794.9M$805.5M$814.5M